Minimal Residual Disease Testing Market Report 2026

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.8 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to growing prevalence of hematological malignancies, advancements in molecular diagnostic technologies, rising awareness about minimal residual disease, increasing adoption of precision medicine, supportive government healthcare initiatives.

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to technological advancements in nGS and digital PCR, expansion of cancer research funding, increasing collaborations between diagnostic and pharmaceutical companies, rising demand for personalized treatment monitoring, growth in emerging markets healthcare infrastructure. Major trends in the forecast period include liquid biopsy adoption, personalized cancer monitoring, early detection & prognosis improvement, integration of molecular diagnostics, expansion of oncology research.

The rising prevalence of cancer is expected to drive the growth of the minimal residual disease (MRD) testing market. Cancer is a condition in which some of the body's cells grow uncontrollably and spread to other parts of the body. MRD testing is a highly sensitive method used to detect cancer cells in the body, and it plays a critical role in determining cancer stages. This early detection helps in preventing the disease at an early stage, thus contributing to the growth of the MRD testing market. For example, in January 2023, the National Institutes of Health (NIH), a U.S.-based government agency, projected that in 2023, there would be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States. Therefore, the increasing prevalence of cancer is driving the demand for minimal residual disease testing.

Major companies in the minimal residual disease testing market are launching advanced cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and promote precision medicine for better patient outcomes. For example, the IDT Archer FUSIONPlex Core Solid Tumor Panel is a next-generation sequencing assay used to detect gene fusions and mutations in solid tumors, supporting precision oncology and treatment decision-making. In April 2023, Integrated DNA Technologies (IDT), a U.S.-based provider of genomic solutions, launched this enhanced cancer research testing solution, now offering expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, using a single sample input and providing researchers with a scalable, user-friendly solution that saves time, resources, and costs.

In April 2023, Quest Diagnostics, a U.S.-based clinical laboratory, acquired Haystack Oncology. Through this acquisition, Quest aims to enhance personalized cancer care by integrating Haystack's liquid biopsy technology, which detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. Haystack Oncology Inc. is a U.S.-based biotechnology company specializing in innovative cancer diagnostics.

Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the minimal residual disease testing market by increasing the cost of importing advanced diagnostic equipment and reagents, especially from major manufacturing hubs in Europe and North America. This has impacted the DNA- and RNA-based test segments the most, slowing adoption in regions like Asia-Pacific and Latin America. However, tariffs are also encouraging local manufacturing and investment in domestic diagnostic capabilities, which may enhance supply chain resilience and reduce long-term dependency on imports.

The minimal residual disease testing market research report is one of a series of new reports that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Minimal residual disease (MRD) testing is a highly sensitive diagnostic tool used to detect cancer cells that may remain in the patient's body after treatment. This test helps monitor the effectiveness of cancer treatments and guides future treatment strategies.

The main types of MRD testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing (also known as genetic testing) is a medical examination that identifies changes in chromosomes, genes, or proteins. Technologies used for MRD testing include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. These tests are applied in various contexts such as hematological malignancies, leukemia, lymphoma, and solid tumors. MRD testing is utilized by hospitals, specialty clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.

The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.